Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors

#2082

Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.

Aim(s): Treatment of well-differentiated lung neuroendocrine tumors is challenging.

Materials and methods: 9 patients (median age 62 years, 5 male, 4 female) with advanced well-differentiated (G1-2) lung neuroendocrine tumors with progressive disease treated with EVE.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Kuznetsova A, Gorbunova V, Orel N, Emelianova G, Markovich A,

Keywords: lung neuroendocrine tumors, Everolimus,